R

RELX

Global information analytics and decision tools

Head of Talent & Capability

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
London, UK+1 moreMore locations: Richmond, UK
In Person
People & HRLearning & Development

About the job

Requirements
  • Recognise and incorporate the voice of the business when designing, delivering, and embedding talent practices within RX.
  • Advocate, educate, and influence senior leaders across various expertise areas within Talent and Capability, focusing on business transformation and people-centric approaches.
  • Operate and lead across different geographies and industries, ensuring successful delivery of large-scale, highly visible talent initiatives.
  • Maintain a client-centric approach and build relationships with executive and senior leadership teams, cross-functional teams, and critical stakeholders.
  • Understand and interpret RX business challenges and opportunities, prioritising and aligning Talent and Capability support accordingly.
  • Recognise the impact of artificial intelligence and other global trends on work and roles, and partner with HR leadership and business stakeholders to identify required upskilling and shifts in focus.
  • Have a proven track record of developing and implementing successful talent strategies and working knowledge and experience with Workday.
  • Demonstrate effective leadership and team collaboration skills and the ability to prioritise and manage multiple initiatives.
Responsibilities
  • Collaborate with internal stakeholders to identify and implement Talent and Capability approaches that support RX’s business objectives.
  • Advocate and implement RELX leadership and development programs within RX, focusing on elevating manager capability, shaping a high-performance RX culture, and building a strong talent pipeline of future leaders.
  • Represent the needs and interests of RX in RELX-wide Talent and Capability discussions and initiatives, ensuring final outcomes are relevant, accessible, and high-value with a compelling RX narrative.
  • Promote a culture of continuous growth and curiosity, using data and metrics to monitor the quality, effectiveness, and overall user experience of talent initiatives within RX.
  • Coordinate RELX Talent Review activities with business leaders and HR partners to identify critical positions, talent readiness, and succession pipelines; support strategies with leaders to address readiness gaps, both technical and behavioural, and enhance purposeful careers.
  • Drive a culture of feedback and recognition to support business outcomes and a meaningful employee experience, working with colleagues across the global HR organisation to ensure integrated and aligned approaches for employees and leaders.
  • Manage the overall divisional training plan and be accountable for the Talent and Capability profit and loss.

About the company

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Get referred to RELX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 revenue grew 7%; Legal grew 10%; Risk grew 8%.
  • February 24, 2026 Lexis+ with Protégé launched globally, expanding AI workflow adoption.
  • September 3, 2026 Doctrine closes, targeting one million European legal professionals.

What critics are saying

  • Anthropic and Thomson Reuters compressed legal AI pricing after February 2026 market shock.
  • Harvey and Legora court law schools in 2026, training future buyer cohorts elsewhere.
  • Exhibitions face Middle East event uncertainty through 2026, threatening margins and calendar-dependent cash flows.

What makes RELX unique

  • LexisNexis’ 200 billion-document corpus still beats generic legal AI models.
  • September 3, 2026 Doctrine acquisition deepens RELX’s European legal AI workflow moat.
  • H1 2026 subscriptions supplied 62% of revenue, stabilizing cash generation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Wellness Program
  • Mental Health Support
  • Family Planning Benefits
  • Health Savings Account/Flexible Spending Account
  • Flexible Work Hours

Company News

Yahoo Finance
Oct 22nd, 2026
RELX reaffirms 2026 outlook as nine-month underlying revenue grows 7%, led by Legal at 10%

RELX, the global provider of information-based analytics and decision tools, reported underlying revenue growth of 7% for the first nine months of 2026. It reaffirmed its full year outlook. Legal grew 10%, Risk 8%, and Scientific, Technical & Medical 6%. Exhibitions rose 4%, held back by disruption in the Middle East. Growth came from AI-enabled analytics and decision tools. RELX's research-grade AI workspace, LeapSpace, is seeing rapid usage growth. RELX expects another year of strong underlying growth in revenue and adjusted operating profit, as well as strong growth in adjusted earnings per share at constant currency.

Citybiz
Apr 28th, 2026
RELX to Acquire Legaltech Platform Doctrine in European AI Push

RELX Group has entered into an agreement to acquire French legal technology company Doctrine, a move that would expand its... Read More

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process